Press Releases - Daiichi Sankyo US
WEBNews, Events, Updates, Breakthroughs. Journalists may direct questions to [email protected]. Or click here for direct contact information for Daiichi Sankyo U.S. Public Affairs team. Press announcements are archived by release date, searchable by topic: Email Alert
News Room - Daiichi Sankyo US
WEBDaiichi Sankyo Europe's Statement Regarding Esperion Therapeutics' Complaint. Industry Veteran, Dr. Mark Rutstein, Joins Daiichi Sankyo to Lead Global Oncology Clinical Development Program. Daiichi Sankyo, Inc. has taken measures to contribute to the overall effort to limit the spread of the virus that causes COVID-19.
U.S. News Room - Daiichi Sankyo US
WEBFeb 19, 2024 · Tokyo and Basking Ridge, NJ – (February 19, 2024) – Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the U.S. for the treatment of adult patients with locally advanced or metastatic nonsquamous non …
Passion for innovation. Compassion for patients. - Daiichi Sankyo US
WEBFor people affected by cancer, Daiichi Sankyo turns hope into possibility. Possibility into reality. Our collective craft is medicine. We’re transforming how cancer and other disease are treated. More than 120 year of heritage inspires us to meet new challenges.
Daiichi Sankyo and Merck Announce Global Development and ...
WEBOct 19, 2023 · Daiichi Sankyo (TSE: 4568) and Merck (known as MSD outside of the United States and Canada) (NYSE: MRK) have entered into a global development and commercialization agreement for three of Daiichi Sankyo’s DXd antibody drug conjugate (ADC) candidates: patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd) and raludotatug deruxtecan (R ...
U.S. News Room - Daiichi Sankyo US
WEBOct 24, 2022 · Submission based on QuANTUM-First results showing quizartinib plus chemotherapy significantly improved overall survival compared to chemotherapy alone. Tokyo and Basking Ridge, NJ – (October 24, 2022) – Daiichi Sankyo (TSE: 4568) received notification of acceptance by the U.S. Food and Drug Administration (FDA) of …
Press Releases - Daiichi Sankyo US
WEBSep 13, 2024 · Daiichi Sankyo and AstraZeneca’s ENHERTU achieved a 61.6% progression-free survival rate at one year in patients with active or stable brain metastases in DESTINY-Breast12. Largest prospective trial of ENHERTU in this patient population. Tokyo and Basking Ridge, NJ – (September 13, 2024) – Results from the DESTINY-Breast12 phase 3b/4 ...
U.S. News Room - Daiichi Sankyo US
WEBDec 23, 2021 · Designed using Daiichi Sankyo’s proprietary DXd ADC technology, patritumab deruxtecan is comprised of a fully human anti-HER3 IgG1 monoclonal antibody attached to a topoisomerase I inhibitor payload (an exatecan derivative, DXd) via a stable tetrapeptide-based cleavable linker.
Daiichi Sankyo and AstraZeneca Enter New Global Development …
WEBDaiichi Sankyo and AstraZeneca will share equally development and commercialization costs as well as profits from DS-1062 worldwide, except for Japan. Daiichi Sankyo is expected to book sales in U.S., certain countries in Europe, and certain other markets where Daiichi Sankyo has affiliates.
Daiichi Sankyo Highlights Progress in Creating New Standards of …
WEBMay 21, 2024 · Data at ASCO showcasing the company’s progress in creating new standards of care for patients with cancer will include the late-breaking positive results of the DESTINY-Breast06 phase 3 trial (LBA #1000) evaluating ENHERTU ® (trastuzumab deruxtecan) compared to standard of care chemotherapy in patients with HR positive, HER2 low (IHC 1+ or ...